NEET PG pharmacology questions

Phenytoin is metabolized by hepatic CYP2C9/2C19 enzymes that become saturated near therapeutic concentrations, converting elimination from first-order to zero-order (Michaelis-Menten) kinetics. Once saturated, a constant amount (not a constant fraction) of drug is eliminated per unit time, so small dose increases cause disproportionately large rises in steady-state plasma concentration. This is why phenytoin dose increments must be small once levels approach the therapeutic range, with close monitoring for toxicity. Ethanol and high-dose aspirin show a similar saturation kinetics pattern.

• B. Enterohepatic recirculation prolongs drug action but does not explain disproportionate, dose-dependent increases in plasma level with small dose changes.
• C. A high volume of distribution would lower, not raise, plasma concentration, and does not explain non-linear kinetics.
• D. P-glycoprotein efflux affects brain penetration, not the disproportionate rise in systemic plasma concentration with dose increase.

Loading dose is calculated as (Vd x target plasma concentration) / bioavailability. Here, Vd = 1.5 L/kg x 70 kg = 105 L, and target concentration = 4 mg/L, giving 105 L x 4 mg/L = 420 mg, divided by bioavailability of 1 (100%) = 420 mg. The loading dose achieves the desired plasma concentration quickly, independent of the drug's half-life, and is especially important for drugs with a long half-life where steady state would otherwise take many hours to reach. Maintenance dose, in contrast, depends on clearance.

• A. This overestimates the dose and would result from an arithmetic error in multiplying Vd by target concentration.
• C. This figure results from using body weight directly as volume of distribution in liters instead of multiplying by the Vd per kg value.
• D. This value is one-quarter of the correct loading dose and does not correspond to the correct Vd x Cp calculation.

Context-sensitive half-time refers to the time required for plasma drug concentration to decrease by 50% after stopping an infusion, and this value increases with the duration of the infusion because peripheral (less well-perfused) tissue compartments become progressively saturated and continue returning drug to plasma. This differs from the fixed elimination half-life seen after a single bolus dose. Propofol and fentanyl are classic examples where prolonged infusions markedly prolong recovery time compared to short infusions or boluses. This concept is clinically important for titrating infusion duration in anesthesia and critical care sedation.

• A. Enzyme induction typically takes days and would speed, not slow, recovery, and is not the mechanism here.
• B. Zero-order elimination describes saturation of metabolic enzymes, not the tissue redistribution phenomenon underlying context-sensitive half-time.
• D. Changes in protein binding are not the primary mechanism; tissue compartment saturation and redistribution kinetics are.

Absolute bioavailability (F) is calculated as the ratio of AUC after extravascular (oral) administration to AUC after intravenous administration, when the same dose is given by both routes: F = AUC(oral)/AUC(IV) = 80/200 = 0.4, or 40%. This reflects the fraction of the administered dose that reaches systemic circulation unchanged, accounting for incomplete absorption and first-pass hepatic metabolism. Intravenous administration is used as the reference standard because it achieves 100% bioavailability by definition. Oral bioavailability is a key determinant of oral dosing requirements relative to the IV dose.

• A. This figure does not match the correct ratio calculation of 80/200.
• B. This value represents the AUC of the oral route in mg.h/L, not the bioavailability percentage.
• D. This value does not correspond to the correct AUC ratio and would require different AUC figures.

Competitive antagonists bind reversibly to the same receptor site as the agonist, producing a parallel rightward shift of the dose-response curve without reducing the maximal efficacy, because sufficient agonist concentration can still displace the antagonist and achieve full response. This is reflected pharmacologically as an increase in the EC50 without a change in Emax. In contrast, non-competitive antagonists reduce the maximal response (Emax) because they bind to a different site or irreversibly inactivate the receptor, and increasing agonist concentration cannot overcome this. This distinction is tested using Schild plot analysis in pharmacology.

• A. Irreversible antagonism permanently reduces available receptors and would depress the maximal response, not merely shift the curve rightward.
• B. Physiological antagonism involves two agonists acting on different receptors with opposing physiological effects, not a single antagonist shifting one agonist's curve.
• C. Non-competitive antagonism reduces the maximal response (lowers Emax), which is not seen in this parallel shift with unchanged maximum.

Therapeutic drug monitoring is most valuable for drugs with a narrow therapeutic index, where the plasma concentration range producing efficacy is close to the range causing toxicity, and where there is significant inter-individual variability in pharmacokinetics (as with warfarin, phenytoin, lithium, digoxin, and aminoglycosides). In such drugs, clinical signs of underdosing or overdosing may be absent, delayed, or difficult to distinguish from the disease itself, making a quantifiable biomarker necessary to guide safe and effective dosing. First-pass metabolism, protein binding, and renal elimination are pharmacokinetic properties that influence dosing but do not by themselves justify routine monitoring unless the therapeutic index is also narrow.

• A. Renal elimination of unchanged drug matters for dose adjustment in renal impairment but does not alone necessitate therapeutic drug monitoring.
• B. High protein binding affects free drug fraction but many highly protein-bound drugs with wide therapeutic indices do not require routine monitoring.
• C. Extensive first-pass metabolism affects bioavailability and dosing route but is not the primary justification for monitoring plasma levels.

Simvastatin is extensively metabolized by hepatic CYP3A4. Macrolide antibiotics such as clarithromycin and erythromycin are potent CYP3A4 inhibitors, and co-administration markedly raises plasma statin concentrations, increasing the risk of dose-dependent toxicity including myopathy and rhabdomyolysis, presenting with myalgia, weakness, elevated creatine kinase, and myoglobinuria (dark urine). This interaction is well recognized, and azithromycin (a weaker CYP3A4 inhibitor) is often preferred over clarithromycin or erythromycin in patients on statins metabolized by this pathway. Statins such as rosuvastatin and pravastatin, which are not significantly metabolized by CYP3A4, are safer alternatives in such patients.

• A. Protein binding displacement is not the recognized mechanism of this statin-macrolide interaction.
• B. Simvastatin is primarily eliminated via hepatic metabolism, not renal tubular secretion, so this is not the relevant mechanism.
• C. Glucuronidation is not the major elimination pathway for simvastatin, and enzyme induction would lower, not raise, drug levels.

Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, which increases the metabolism and clearance of both the estrogen and progestin components of combined oral contraceptive pills, lowering their plasma levels below the threshold needed for reliable ovulation suppression. This leads to contraceptive failure and unintended pregnancy, so women on rifampicin-containing anti-tubercular therapy should be counseled to use alternative or additional non-hormonal contraceptive methods such as barrier methods or copper intrauterine devices during treatment. This is an important drug interaction to recognize given the widespread use of rifampicin under the National TB Elimination Programme (NTEP) in India.

• A. Rifampicin has no direct antagonist action at steroid hormone receptors; its effect is pharmacokinetic via enzyme induction.
• B. Rifampicin does not significantly impair intestinal absorption of oral contraceptive steroids.
• C. Protein binding displacement is not the mechanism of this well-established interaction; enzyme induction accelerating metabolism is.

Conjugation reactions, including glucuronidation, acetylation, sulfation, and methylation, are classified as Phase II reactions because they attach an endogenous polar group to the drug or its metabolite, greatly increasing water solubility for renal or biliary excretion. Phase I reactions (oxidation, reduction, hydrolysis) instead unmask or create a functional group, usually via cytochrome P450 enzymes, and may or may not inactivate the drug. Glucuronidation is catalyzed by UDP-glucuronosyltransferases located in the endoplasmic reticulum. Many drugs undergo sequential Phase I followed by Phase II metabolism before elimination.

• A. Hydrolysis cleaves ester or amide bonds using water and does not add a glucuronic acid group.
• B. Reduction reactions add electrons/hydrogen and do not involve attaching a conjugate.
• C. Oxidation introduces or exposes a functional group via cytochrome P450, not a conjugation step.

Pralidoxime is an oxime that reactivates acetylcholinesterase by displacing the organophosphate group bound to the enzyme's active site, regenerating functional enzyme that can again hydrolyze acetylcholine. It is most effective when given early because the phosphorylated enzyme complex undergoes a time-dependent process called aging, in which the complex becomes resistant to reactivation by oxime therapy. Once aging has occurred, the enzyme-phosphate bond becomes essentially irreversible and new enzyme synthesis is required, which takes days to weeks. Pralidoxime is particularly effective at reversing nicotinic effects such as muscle fasciculations and weakness, complementing atropine's action on muscarinic symptoms.

• A. Pralidoxime acts on the enzyme-organophosphate complex, not by directly hydrolyzing free organophosphate in plasma.
• B. Pralidoxime reactivates existing inhibited enzyme; it does not stimulate synthesis of new enzyme.
• D. This describes atropine's action, not pralidoxime's mechanism.

Tamsulosin is a selective alpha-1A antagonist with greater affinity for the alpha-1A subtype that predominates in prostatic smooth muscle and bladder neck compared to the alpha-1B subtype found in vascular smooth muscle. This selectivity allows it to relieve bladder outlet obstruction in BPH with a lower incidence of orthostatic hypotension compared to non-selective alpha-1 blockers like prazosin. Prazosin blocks alpha-1A, alpha-1B, and alpha-1D subtypes relatively equally, so it causes more significant blood pressure lowering and postural hypotension. Tamsulosin is therefore favored in elderly patients with BPH who are prone to orthostatic hypotension or are normotensive.

• A. Prazosin is a non-selective alpha-1 blocker and causes more orthostatic hypotension.
• C. Phentolamine is a non-selective, reversible alpha blocker used short-term, not for BPH, and causes marked hypotension.
• D. Phenoxybenzamine is a non-selective, irreversible alpha blocker used mainly in pheochromocytoma, with significant hypotensive effects.

Salbutamol is a relatively selective beta-2 adrenergic agonist that causes bronchodilation with minimal action on cardiac beta-1 receptors, making it the preferred bronchodilator in patients with coexisting ischemic heart disease. Isoproterenol and epinephrine act on both beta-1 and beta-2 receptors, producing significant increases in heart rate and myocardial oxygen demand, which risks precipitating angina or arrhythmia in a patient with coronary artery disease. Ephedrine is a mixed-acting sympathomimetic with both alpha and beta effects, including cardiac stimulation, and is not used for acute bronchospasm. The beta-2 selectivity of salbutamol allows effective bronchodilation while sparing the heart from excessive stimulation.

• B. Ephedrine has mixed direct and indirect sympathomimetic action with cardiac stimulatory effects unsuitable in coronary artery disease.
• C. Epinephrine acts on alpha, beta-1, and beta-2 receptors and can precipitate arrhythmia or worsen ischemia.
• D. Isoproterenol stimulates beta-1 as well as beta-2 receptors, causing marked tachycardia and increased myocardial oxygen demand.

Prostaglandin F2-alpha analogues such as latanoprost lower intraocular pressure predominantly by increasing uveoscleral outflow of aqueous humor, achieved through relaxation and remodeling of the extracellular matrix of the ciliary muscle, which widens the spaces between muscle bundles. This mechanism contrasts with pilocarpine, a muscarinic agonist that contracts the ciliary muscle to open the trabecular meshwork and increase conventional outflow, and with timolol, a non-selective beta blocker that reduces aqueous humor production by the ciliary epithelium. Latanoprost is typically given once daily at night and is now a first-line agent for open-angle glaucoma due to its efficacy and once-daily dosing. Common side effects include conjunctival hyperemia, increased iris pigmentation, and eyelash growth.

• A. This describes the mechanism of pilocarpine, a muscarinic agonist, not a prostaglandin analogue.
• C. Prostaglandin analogues act pharmacologically on the ciliary muscle and extracellular matrix, not by creating a surgical drainage channel.
• D. This describes the mechanism of timolol, a beta blocker, not a prostaglandin analogue.

This patient has developed malignant hyperthermia, a life-threatening hypermetabolic reaction triggered by succinylcholine and volatile anesthetics in genetically susceptible individuals with ryanodine receptor (RYR1) mutations, causing uncontrolled calcium release from the sarcoplasmic reticulum. Dantrolene is the definitive treatment because it binds to the ryanodine receptor and inhibits calcium release from the sarcoplasmic reticulum, reducing muscle rigidity and halting the hypermetabolic state. Supportive measures include stopping the triggering agent immediately, active cooling, and management of hyperkalemia and acidosis, but dantrolene is the only specific pharmacologic antidote. Prompt recognition and treatment are critical since untreated malignant hyperthermia carries high mortality.

• A. Diazepam may be used for sedation but does not address the underlying calcium release defect.
• C. Dexmedetomidine is a sedative and has no role in reversing the calcium-mediated muscle hypermetabolism of malignant hyperthermia.
• D. Bromocriptine is used in neuroleptic malignant syndrome, a different condition, not malignant hyperthermia.

Neostigmine inhibits acetylcholinesterase, increasing acetylcholine at both nicotinic (neuromuscular junction, desired effect) and muscarinic receptors (cardiac, glandular, smooth muscle, unwanted effect). The resulting muscarinic excess causes bradycardia, bronchospasm, salivation, and increased gut motility. Glycopyrrolate, a quaternary antimuscarinic that does not cross the blood-brain barrier, blocks these muscarinic receptors without affecting the desired nicotinic reversal of paralysis. This combination allows safe reversal of neuromuscular blockade while preventing cholinergic crisis-like side effects.

• A. Glycopyrrolate is an antimuscarinic, not a cholinesterase inhibitor, and does not enhance nicotinic transmission.
• C. Tachyphylaxis to neostigmine is not the clinical concern being addressed by this combination.
• D. Glycopyrrolate has no activity at nicotinic receptors or at the neuromuscular junction.

Valproate is strongly associated with neural tube defects, including meningomyelocele and spina bifida, when taken during the first trimester of pregnancy, due to its interference with folate metabolism and histone deacetylase inhibition affecting neural tube closure. This risk is dose-dependent and is one of the key reasons valproate is avoided in women of childbearing age with epilepsy when alternatives exist. Phenytoin is instead associated with fetal hydantoin syndrome, characterized by craniofacial anomalies, limb defects, and growth retardation, a distinct teratogenic pattern.

• A. Phenobarbitone is not classically associated with neural tube defects.
• C. Phenytoin causes fetal hydantoin syndrome with craniofacial and limb anomalies, not neural tube defects.
• D. Carbamazepine carries a smaller but present neural tube defect risk; it is not the drug most strongly linked to this anomaly.

Ethosuximide selectively blocks T-type (low-threshold) calcium channels in thalamic neurons, which generate the rhythmic burst firing underlying the 3 Hz spike-and-wave discharges characteristic of absence seizures. It is a first-line drug for absence seizures and has no significant action against generalized tonic-clonic seizures. Valproate is also effective in absence seizures and is preferred when tonic-clonic seizures coexist, but its primary mechanism is different, involving sodium channel blockade and increased GABA levels. Phenytoin and carbamazepine are ineffective for absence seizures and may even worsen them.

• A. Phenytoin is ineffective against absence seizures and can worsen them; it acts on sodium channels, used for tonic-clonic and focal seizures.
• C. Carbamazepine is ineffective for absence seizures and can exacerbate them; it acts via sodium channel blockade, used for focal and tonic-clonic seizures.
• D. Valproate is effective in absence seizures but acts mainly via sodium channel blockade and GABA enhancement, not T-type calcium channel blockade.

The HLA-B*1502 allele, prevalent in certain South and Southeast Asian populations including Han Chinese, Thai, and Indian populations, is strongly associated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Current guidelines recommend screening for this allele before initiating carbamazepine in at-risk ethnic groups, and avoiding the drug in those who test positive. The mechanism involves altered presentation of the drug or its metabolites by this HLA variant to T cells, triggering a cytotoxic immune response against keratinocytes.

• A. HLA-B27 is associated with seronegative spondyloarthropathies, not drug-induced Stevens-Johnson syndrome.
• C. HLA-DR4 is associated with autoimmune conditions such as rheumatoid arthritis, not carbamazepine hypersensitivity.
• D. CYP2C9 variants affect warfarin and phenytoin metabolism, not carbamazepine-induced skin reactions.

Carbidopa is a peripheral dopa decarboxylase inhibitor that does not cross the blood-brain barrier. By inhibiting the conversion of levodopa to dopamine in peripheral tissues, it increases the fraction of an administered dose of levodopa that reaches the central nervous system intact. This allows a lower total dose of levodopa to be used, which reduces peripheral dopamine-related adverse effects such as nausea, vomiting, and cardiovascular effects, while central therapeutic levels of dopamine are maintained.

• B. Carbidopa has no monoamine oxidase inhibitory activity; that mechanism describes drugs such as selegiline.
• C. Carbidopa acts as an enzyme inhibitor, not as a dopamine receptor antagonist.
• D. Carbidopa inhibits, rather than increases, decarboxylation of levodopa, and this inhibition occurs peripherally, not in the striatum.

Clozapine carries a risk of agranulocytosis, a potentially fatal idiosyncratic adverse effect occurring in approximately 1 percent of patients, most commonly within the first six months of therapy. Regulatory protocols mandate baseline and then weekly absolute neutrophil counts for the first six months, followed by less frequent monitoring (such as every two weeks, then monthly) if counts remain normal, continuing for the duration of treatment. Therapy must be stopped immediately if the absolute neutrophil count falls below the threshold defining agranulocytosis.

• A. Liver function test monitoring is not the primary mandated safety surveillance associated with clozapine use.
• B. Although myocarditis is a recognized risk, routine mandatory monitoring specifically for clozapine safety centers on neutrophil counts, not an annual electrocardiogram alone.
• C. Clozapine characteristically does not raise prolactin significantly, unlike many typical antipsychotics and risperidone; prolactin monitoring is not the mandated safety protocol.

This presentation, torticollis with oculogyric crisis occurring within hours of starting a high-potency typical antipsychotic, is an acute dystonic reaction, caused by dopamine D2 receptor blockade leading to a relative central cholinergic excess in the basal ganglia. Treatment is with an anticholinergic or antihistaminic agent with anticholinergic properties, such as intravenous or intramuscular benztropine, or intramuscular promethazine, which rapidly relieve the muscle spasm by restoring the dopaminergic-cholinergic balance. Symptoms typically resolve within minutes of parenteral administration.

• A. Benzodiazepines can provide adjunct relief of anxiety but are not the primary or sole treatment of choice for acute dystonia; an anticholinergic agent is specifically indicated.
• B. Sodium valproate has no established role in the acute treatment of antipsychotic-induced dystonic reactions.
• D. Propranolol, a beta-blocker, is used for antipsychotic-induced akathisia, not acute dystonia.

Loop diuretics such as furosemide inhibit the Na-K-2Cl cotransporter not only in the thick ascending limb of the loop of Henle but also in the stria vascularis of the inner ear, disturbing endolymph ion composition. Ototoxicity is dose- and rate-dependent and is markedly increased by rapid intravenous bolus administration of high doses, especially in patients with renal impairment where drug clearance is reduced and plasma levels remain elevated longer. The hearing loss is usually reversible but can become permanent with repeated insults. Slow infusion and avoiding high cumulative doses reduce this risk.

• A. Hypokalemia is a metabolic complication of loop diuretics but is not the mechanism linked to ototoxicity.
• B. ACE inhibitors do not potentiate loop diuretic ototoxicity.
• C. Oral administration produces lower peak plasma concentrations and is associated with much lower ototoxic risk than rapid IV bolus.

Thiazide diuretics such as hydrochlorothiazide cause hyperglycemia by reducing insulin secretion and inducing mild insulin resistance, hyperuricemia by competing with uric acid for proximal tubular secretion, and hypercalcemia by enhancing calcium reabsorption in the distal convoluted tubule via increased sodium-calcium exchange. This combination of metabolic effects is distinctive to thiazides among antihypertensive classes. Loop diuretics, in contrast, increase urinary calcium excretion and cause hypocalcemia. Thiazides are therefore used cautiously in diabetics and gout patients but can be beneficial in patients with osteoporosis or hypercalciuria.

• A. Amlodipine, a calcium channel blocker, does not cause hyperglycemia, hyperuricemia, or hypercalcemia.
• B. Losartan, an angiotensin receptor blocker, tends to lower uric acid and does not cause this metabolic triad.
• D. Furosemide, a loop diuretic, causes hypocalcemia rather than hypercalcemia due to increased calcium excretion.

Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, which upregulates LDL receptor expression and increases clearance of circulating LDL cholesterol. Baseline liver function tests are recommended before starting therapy because statins can rarely cause hepatotoxicity with transaminase elevation, and liver enzymes are rechecked if the patient develops symptoms suggestive of liver injury. Creatine kinase is not routinely monitored in asymptomatic patients but should be checked if muscle symptoms develop, since statins can cause myopathy and rarely rhabdomyolysis. Current guidelines no longer recommend routine periodic liver enzyme monitoring once a normal baseline is confirmed.

• A. Microsomal triglyceride transfer protein is inhibited by lomitapide, used in homozygous familial hypercholesterolemia.
• B. Cholesteryl ester transfer protein is the target of inhibitors like anacetrapib, not statins.
• C. PCSK9 is the target of monoclonal antibodies like evolocumab and alirocumab, not statins.

Heparin-induced thrombocytopenia (HIT) is caused by IgG antibodies directed against complexes of platelet factor 4 and heparin; these immune complexes bind to and activate platelets via their Fc receptors, triggering platelet aggregation, thrombocytopenia, and paradoxically a high risk of arterial and venous thrombosis, as seen here with the ischemic limb. Heparin must be stopped immediately and replaced with a non-heparin anticoagulant such as argatroban or fondaparinux, since even low-molecular-weight heparin cross-reacts with the antibodies. Platelet transfusion is avoided as it can worsen thrombosis. Diagnosis is supported by a 4T score and confirmed with PF4-heparin antibody ELISA or functional assays.

• B. HIT is immune-mediated platelet activation, not direct marrow toxicity.
• C. Anti-GPIIb/IIIa antibodies are not the mechanism of HIT; this describes a different immune thrombocytopenic process.
• D. DIC would show coagulopathy with prolonged PT/aPTT and falling fibrinogen, not an isolated immune thrombocytopenia with thrombosis.

In life-threatening warfarin-associated bleeding, four-factor prothrombin complex concentrate (containing factors II, VII, IX, and X) is the preferred reversal agent because it rapidly normalizes the INR within minutes, unlike fresh frozen plasma which requires large volumes and takes longer to prepare and infuse. Intravenous vitamin K should be given concurrently to sustain factor synthesis, since PCC has a shorter duration of action than the half-life of warfarin. Oral vitamin K acts too slowly for an emergency. Protamine sulfate reverses heparin, not warfarin, by binding to it ionically.

• A. Fresh frozen plasma requires larger volumes and takes longer to reverse INR compared to prothrombin complex concentrate.
• C. Protamine sulfate neutralizes heparin and has no effect on warfarin-induced coagulopathy.
• D. Oral vitamin K takes many hours to raise clotting factor levels and is not appropriate for immediate reversal in active major bleeding.

Dabigatran, a direct thrombin (factor IIa) inhibitor, has a predictable dose-dependent anticoagulant effect with a wide therapeutic window and fixed dosing, so routine coagulation monitoring is not required in most patients, unlike warfarin which has a narrow therapeutic index and variable pharmacokinetics necessitating regular INR checks. Warfarin's effect is influenced by diet, genetic polymorphisms (VKORC1, CYP2C9), and multiple drug interactions, making individualized dose titration essential. Dabigatran is renally cleared, so renal function should be monitored periodically, but this is different from routine coagulation monitoring. In specific situations such as suspected overdose or need for emergency surgery, specialized tests like dilute thrombin time can assess dabigatran activity.

• A. INR is specific to vitamin K antagonist monitoring and is not used to monitor dabigatran.
• B. Platelet count monitoring is not a requirement for dabigatran therapy.
• C. Serum potassium is not a parameter used to monitor dabigatran's anticoagulant effect.

Beta-lactam antibiotics such as amoxicillin bind to and inhibit penicillin-binding proteins (transpeptidases) that catalyze the final cross-linking step of peptidoglycan synthesis in the bacterial cell wall, leading to cell lysis, especially in actively dividing bacteria. The most common mechanism of resistance is production of beta-lactamase enzymes, which hydrolyze the beta-lactam ring and inactivate the drug before it can reach its target. This is why beta-lactamase inhibitors like clavulanic acid are combined with amoxicillin to protect it from enzymatic degradation. Other resistance mechanisms include altered PBPs with reduced drug affinity, as seen in methicillin-resistant Staphylococcus aureus.

• A. Folic acid synthesis inhibition describes sulfonamides, not beta-lactams.
• C. 30S ribosomal inhibition and ribosomal protection describe tetracyclines, not beta-lactams.
• D. DNA gyrase inhibition and efflux pump resistance describe fluoroquinolones, not beta-lactams.

Aminoglycosides like gentamicin accumulate in renal proximal tubular cells and the inner ear, causing dose- and duration-dependent nephrotoxicity and ototoxicity (both vestibular and cochlear). Serum creatinine should be monitored regularly to detect early renal impairment, and audiometry or clinical assessment for hearing loss, tinnitus, and vestibular symptoms should be performed, especially with prolonged therapy, higher doses, or pre-existing renal dysfunction. Nephrotoxicity is usually reversible on stopping the drug, but ototoxicity can be irreversible due to hair cell damage in the cochlea. Dosing is often guided by peak and trough serum drug levels to minimize toxicity while maintaining efficacy.

• B. Blood count and bilirubin are not the parameters used to detect aminoglycoside toxicity.
• C. Electrolyte and cardiac monitoring are not specific to aminoglycoside toxicity.
• D. Liver function and amylase are not the relevant toxicities monitored for aminoglycosides.

Red man syndrome results from non-immune, direct mast cell and basophil degranulation by vancomycin, causing histamine release that is rate-dependent rather than dose-dependent. Slowing the infusion rate (each gram infused over at least 60 minutes, or longer for higher doses) reduces the peak rate of histamine release and prevents the reaction. It is not a true IgE-mediated allergy, so it does not require stopping the drug or switching agents in most cases. Antihistamines (not corticosteroids) are used for treatment/prophylaxis if rapid infusion cannot be avoided.

• A. A rapid bolus would worsen histamine release and precipitate the reaction, not prevent it.
• B. Switching antibiotics is unnecessary since slowing the infusion rate prevents the reaction in most patients.
• C. Corticosteroids are not the standard preventive measure; this is a histamine-mediated, not purely inflammatory or immune, reaction.

Fluoroquinolones chelate magnesium in growing cartilage, impairing integrin-mediated chondrocyte-matrix interactions and leading to cartilage erosions, particularly in weight-bearing joints, as demonstrated in juvenile animal studies. This arthropathy risk is the main reason fluoroquinolones are traditionally avoided in children and pregnant women, although they may be used in specific situations like multidrug-resistant infections or cystic fibrosis exacerbations when benefits outweigh risks. Teeth staining is a tetracycline effect, not fluoroquinolone. Phototoxicity does occur with fluoroquinolones but is not the primary reason for avoidance in children.

• A. Tooth discoloration is characteristic of tetracyclines binding to calcium in developing enamel, not fluoroquinolones.
• B. Ototoxicity is more typical of aminoglycosides and loop diuretics, not a defining fluoroquinolone concern in children.
• D. Phototoxicity can occur with fluoroquinolones but is not the main reason they are restricted in the pediatric age group.

Tetracyclines form stable calcium chelation complexes that get incorporated into the hydroxyapatite of developing teeth and bone during mineralization. On exposure to light, the deposited tetracycline-calcium orthophosphate complex oxidizes, producing permanent yellow-brown to gray discoloration. This occurs when the drug is given during tooth development, from the second half of pregnancy through about 8 years of age, and is a key reason tetracyclines are avoided in this group. The discoloration is irreversible once teeth have erupted.

• A. The discoloration is a chemical deposition effect, not an immune-mediated pulpal inflammation.
• B. The staining arises from within the tooth structure itself, not from surface bacterial plaque.
• C. The mechanism is calcium chelation incorporated during mineralization, not a separate oxidative process on mature enamel crystals.

Gray baby syndrome occurs in neonates, especially preterm infants, because immature hepatic glucuronyl transferase activity and reduced renal clearance cause chloramphenicol to accumulate to toxic levels. High drug levels impair mitochondrial oxidative phosphorylation in multiple tissues, producing vomiting, abdominal distension, hypotension, cyanosis, and cardiovascular collapse, which carries high mortality if untreated. This is distinct from the two hematologic toxicities of chloramphenicol: a dose-related reversible bone marrow suppression and a rare idiosyncratic, dose-independent aplastic anemia. Gray baby syndrome is a toxicity of drug accumulation, not a marrow or immune effect.

• A. This describes the mechanism of idiosyncratic aplastic anemia, which is unrelated to drug levels and does not present with this acute cardiovascular picture.
• B. There is no immune-mediated hemolytic mechanism described for chloramphenicol toxicity in neonates.
• D. This describes the dose-dependent reversible bone marrow suppression (anemia, leukopenia), not the acute systemic toxicity seen here.

Linezolid is a weak, reversible, nonselective monoamine oxidase inhibitor. When combined with serotonergic drugs such as SSRIs, it can cause excess synaptic serotonin accumulation, producing serotonin syndrome, characterized by agitation, autonomic instability, hyperthermia, and neuromuscular findings like hyperreflexia and clonus. This combination should generally be avoided; if linezolid is essential, the serotonergic agent should be stopped and the patient monitored closely. Linezolid-associated thrombocytopenia and mitochondrial/lactic acidosis are separate, unrelated toxicities seen with prolonged use.

• A. Linezolid is not a significant cytochrome P450 inhibitor; this is not its mechanism of interaction with serotonergic drugs.
• B. Mitochondrial toxicity with lactic acidosis occurs with prolonged linezolid use but does not explain this acute serotonergic presentation.
• C. Thrombocytopenia is a recognized linezolid toxicity with prolonged therapy but does not explain this neuroexcitatory, hyperthermic syndrome.

Under the NTEP (formerly RNTCP), new cases of drug-sensitive tuberculosis receive a daily regimen with four first-line drugs, isoniazid, rifampicin, pyrazinamide and ethambutol, during a 2-month intensive phase, followed by a 4-month continuation phase with isoniazid and rifampicin. The programme shifted from thrice-weekly intermittent dosing to daily dosing with fixed-dose combinations to improve efficacy and reduce acquired drug resistance. Streptomycin is reserved for retreatment regimens or specific situations, not first-line new cases. Total standard duration for a new case is therefore 6 months.

• A. This duration and drug combination with streptomycin do not match the current NTEP daily regimen for new drug-sensitive TB cases.
• C. Streptomycin is not part of the first-line regimen for new cases, and pyrazinamide, a key intensive phase drug, is omitted here.
• D. NTEP has shifted to daily dosing, not thrice-weekly, for both phases in the standard regimen.

Metformin is excreted almost entirely unchanged by the kidneys, and in significant renal impairment its clearance falls, leading to drug accumulation. Metformin inhibits mitochondrial respiratory chain complex I and promotes anaerobic glycolysis, increasing lactate production while also impairing hepatic lactate uptake, which together raise the risk of life-threatening lactic acidosis when the drug accumulates. This is why metformin is contraindicated or requires dose reduction/discontinuation at low eGFR thresholds (generally avoided below 30 mL/min/1.73m2) as per current guidelines. Metformin itself does not stimulate insulin secretion, so it carries minimal intrinsic hypoglycemia risk.

• A. This describes sulfonylurea toxicity, not metformin, which is not a sulfonylurea.
• C. Metformin does not stimulate insulin secretion; this describes sulfonylureas, not metformin's mechanism or risk.
• D. SGLT2 inhibition and volume depletion describe SGLT2 inhibitors, not metformin's mechanism.

Sulfonylureas such as glimepiride bind the SUR1 subunit of the ATP-sensitive potassium channel on pancreatic beta cells, closing the channel independent of ambient glucose levels and causing membrane depolarization, calcium influx and insulin release. This insulin secretion is not glucose-dependent, so prolonged or excessive stimulation causes hypoglycemia, a risk markedly increased in renal impairment because reduced clearance prolongs drug and active metabolite levels. Metformin, pioglitazone and acarbose do not stimulate insulin release and essentially never cause hypoglycemia when used alone.

• A. Metformin acts by reducing hepatic gluconeogenesis and does not stimulate insulin secretion, so it does not cause hypoglycemia as monotherapy.
• C. Acarbose delays intestinal carbohydrate absorption and does not cause hypoglycemia when used alone.
• D. Pioglitazone improves peripheral insulin sensitivity via PPAR-gamma activation and does not cause hypoglycemia alone.

SGLT2 inhibitors such as empagliflozin and dapagliflozin block the sodium-glucose cotransporter-2 in the proximal convoluted tubule, reducing glucose reabsorption and causing glucosuria. The resulting glucose-rich urine promotes genital and urinary tract infections, as seen with this patient's vulvovaginal candidiasis. These drugs can also precipitate euglycemic diabetic ketoacidosis because glucosuria lowers blood glucose while insulin deficiency or stress still permits unchecked lipolysis and ketogenesis. The other mechanisms listed describe GLP-1-related, DPP-4 inhibitor, and thiazolidinedione actions, none of which cause glucosuria or genital infections.

• A. This describes the incretin-mediated mechanism of GLP-1 analogues, which does not cause glucosuria.
• B. This describes the mechanism of DPP-4 inhibitors like sitagliptin, which do not cause glucosuria or genital infections.
• C. This describes the mechanism of thiazolidinediones, which improve insulin sensitivity and do not cause glucosuria.

Prolonged exogenous corticosteroid use suppresses the hypothalamic-pituitary-adrenal (HPA) axis through negative feedback on corticotropin-releasing hormone and ACTH secretion, causing adrenal cortex atrophy. Abrupt withdrawal after long-term therapy can precipitate acute adrenal insufficiency, with hypotension, hypoglycemia and shock, because the atrophied adrenal glands cannot immediately resume adequate cortisol production. Gradual tapering allows progressive recovery of endogenous ACTH secretion and adrenal cortisol synthesis, preventing this crisis. Simply switching formulations or briefly increasing the dose does not address the need for gradual HPA axis recovery.

• A. Doubling the dose does not address HPA axis recovery and only prolongs suppression before withdrawal.
• B. Abrupt discontinuation after prolonged therapy risks acute adrenal insufficiency due to HPA axis suppression.
• D. Switching formulation without tapering does not allow the suppressed HPA axis time to recover and still risks adrenal crisis.

Salicylate toxicity classically produces a mixed acid-base disturbance: salicylate directly stimulates the medullary respiratory center producing hyperventilation and a primary respiratory alkalosis, while simultaneously uncoupling oxidative phosphorylation in the Krebs cycle, which causes accumulation of lactic acid, ketoacids and salicylic acid itself, producing a concurrent high anion gap metabolic acidosis. Early in toxicity respiratory alkalosis may dominate, but as toxicity progresses the metabolic acidosis becomes more prominent, and the near-normal pH with low PaCO2 and low HCO3- in this patient reflects this combined picture. The other options describe only a single acid-base abnormality and do not capture the mixed pattern typical of salicylate poisoning.

• B. Salicylates stimulate rather than depress the respiratory center, producing hyperventilation, not respiratory acidosis.
• C. This ignores the concomitant metabolic acidosis from uncoupled oxidative phosphorylation that is characteristic of salicylate toxicity.
• D. This ignores the respiratory center stimulation by salicylate and misattributes the acidosis solely to renal bicarbonate loss.

Paracetamol is normally metabolized mostly by glucuronidation and sulfation, with a small fraction oxidized by CYP2E1 to the reactive and hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by conjugation with hepatic glutathione. In overdose, glutathione stores become depleted, allowing NAPQI to accumulate and cause centrilobular hepatic necrosis. N-acetylcysteine acts as a glutathione precursor and substrate, replenishing glutathione stores and also providing an alternative substrate for direct conjugation of NAPQI, thereby preventing hepatocyte injury. It does not inhibit CYP2E1, chelate the metabolite directly, or reverse already established necrosis.

• A. N-acetylcysteine prevents further hepatocyte injury but does not reverse necrosis that has already occurred.
• B. N-acetylcysteine does not act as a chelating agent for NAPQI.
• D. N-acetylcysteine does not significantly inhibit CYP2E1; its protective effect is through glutathione repletion.

COX-1 is constitutively expressed in gastric mucosa, producing cytoprotective prostaglandins, while COX-2 is the main source of prostaglandins in inflammation and also of endothelial prostacyclin (PGI2), which normally opposes platelet aggregation. Selective COX-2 inhibitors like celecoxib spare COX-1-mediated gastric prostaglandin synthesis, reducing peptic ulcer risk compared with non-selective NSAIDs. However, by inhibiting endothelial COX-2-derived prostacyclin while leaving platelet COX-1-derived thromboxane A2 synthesis intact, they shift the hemostatic balance toward a prothrombotic state, increasing the risk of myocardial infarction and stroke. The other options misstate either the enzyme selectivity or the direction of the cardiovascular and gastric effects.

• A. Non-selective NSAIDs inhibit COX-1 and therefore reduce rather than protect gastric mucosal prostaglandins.
• B. This reverses the mechanism; COX-2 selective drugs, not COX-1 selective drugs, are used for gastric sparing.
• C. COX-2 selective inhibitors spare rather than increase gastric prostaglandin synthesis, and they do carry cardiovascular risk.

ACE inhibitors such as enalapril are classically associated with a fetopathy when used in the second and third trimesters, including oligohydramnios from reduced fetal renal perfusion and urine output, fetal renal failure, pulmonary hypoplasia and skull ossification defects, because angiotensin II is important for fetal renal development and perfusion. Because of this risk, ACE inhibitors should be stopped as soon as pregnancy is confirmed and substituted with a pregnancy-safe antihypertensive. Methyldopa, labetalol and nifedipine are all considered relatively safe and are commonly used first-line agents for hypertension in pregnancy.

• B. Methyldopa is a preferred first-line antihypertensive in pregnancy and is not associated with this fetopathy.
• C. Nifedipine is used safely in pregnancy, including for severe hypertension and preterm labor tocolysis, and does not cause this fetopathy.
• D. Labetalol is commonly used safely in pregnancy and does not cause this pattern of renal fetopathy.

This patient has severe lithium toxicity (level >2.5 mEq/L with neurological and renal features), precipitated by dehydration-induced reduced renal clearance. Lithium is a small ion not bound to plasma proteins, so it is efficiently removed by hemodialysis, which is indicated for severe toxicity with renal impairment or significant neurological symptoms. IV normal saline supports renal lithium excretion while dialysis is arranged. Activated charcoal does not adsorb lithium because it is a small inorganic ion, and bicarbonate alkalinization is used for salicylate, not lithium, toxicity.

• B. Urinary alkalinization enhances elimination of weak acids like salicylates, not lithium.
• C. Activated charcoal does not bind lithium, an inorganic ion without a carbon skeleton.
• D. Switching drugs ignores the acute life-threatening toxicity that needs immediate elimination.

Abrupt cessation of an SSRI/SNRI after regular use can produce discontinuation syndrome, presenting with dizziness, nausea, irritability, and characteristic 'brain zaps' (electric shock sensations), typically beginning within days of stopping the drug and in the absence of autonomic instability or neuromuscular findings. Serotonin syndrome, in contrast, results from excess serotonergic stimulation (usually with a serotonergic drug combination or overdose) and classically shows hyperthermia, clonus, hyperreflexia, and agitation. The absence of fever, clonus, and hyperreflexia here argues against serotonin syndrome. Management of discontinuation syndrome is reassurance or tapering reinstatement rather than cyproheptadine, which is used in serotonin syndrome.

• A. Anticholinergic toxicity causes dry skin, mydriasis, and urinary retention, not reported here.
• B. Serotonin syndrome presents with hyperthermia, clonus, and hyperreflexia, none of which are present here.
• D. Neuroleptic malignant syndrome needs dopamine-blocking agent exposure and causes rigidity with high fever, not seen here.

Naloxone is a competitive opioid receptor antagonist with a short elimination half-life of approximately 60-90 minutes, which is shorter than the duration of action of many opioids including heroin's active metabolite. This mismatch allows re-sedation and respiratory depression to recur once the naloxone effect wanes while the opioid is still active, necessitating repeat dosing or a continuous infusion and close monitoring. Acute tolerance to naloxone does not occur with single dosing, and naloxone has no agonist activity at any dose since it is a pure antagonist.

• A. Naloxone is a pure antagonist without agonist activity at any dose.
• B. Aspiration pneumonia would not produce this rapid, reversible pattern tied to drug half-life.
• D. Tolerance to an antagonist after a single dose does not occur and is not the mechanism here.

This patient has malignant hyperthermia, a hypermetabolic crisis triggered by volatile anesthetics (like halothane) and depolarizing muscle relaxants (succinylcholine) in genetically susceptible individuals with ryanodine receptor mutations, causing uncontrolled calcium release from the sarcoplasmic reticulum. Dantrolene works by blocking ryanodine receptor-mediated calcium release from the sarcoplasmic reticulum in skeletal muscle, directly reversing the hypermetabolic state and muscle rigidity. Myoglobinuria (cola-colored urine) results from rhabdomyolysis due to sustained muscle contraction. Midazolam, physostigmine, and flumazenil have no role in this specific pharmacologic crisis.

• A. Midazolam provides sedation but does not address the underlying calcium release defect.
• B. Flumazenil reverses benzodiazepine effects and has no role in malignant hyperthermia.
• C. Physostigmine reverses anticholinergic toxicity, unrelated to this presentation.

ACE inhibitors block angiotensin-converting enzyme, which also normally degrades bradykinin and substance P. The resulting accumulation of bradykinin in the airways is thought to sensitize sensory nerve endings and stimulate the production of pro-inflammatory mediators like prostaglandins, producing a dry cough in up to 10-20% of patients. This adverse effect is class-specific to ACE inhibitors and resolves on discontinuation, which is why angiotensin receptor blockers (which do not affect bradykinin metabolism) are substituted without recurrence. The cough is not allergic or eosinophilic in nature and chest imaging remains normal.

• A. ACE inhibitors do not block beta-2 receptors; this mechanism belongs to non-selective beta blockers.
• B. Angiotensin II is reduced, not increased, by ACE inhibitors, and this mechanism does not explain cough resolution with ARBs.
• C. There is no eosinophilic infiltration; chest X-ray findings are normal and resolution occurs simply on stopping the drug.

Amiodarone is classified as a Class III antiarrhythmic because its predominant action is blockade of potassium channels, which prolongs the action potential duration and the effective refractory period, though it also has class I, II, and IV properties, making it a broad-spectrum agent. Quinidine and procainamide are Class IA agents that block sodium channels and moderately prolong repolarization. Flecainide is a Class IC agent that markedly blocks sodium channels with minimal effect on repolarization and slows conduction velocity significantly.

• A. Procainamide is a Class IA sodium channel blocker similar to quinidine.
• C. Quinidine is a Class IA sodium channel blocker with moderate effect on repolarization.
• D. Flecainide is a Class IC sodium channel blocker with minimal effect on action potential duration.

This patient is in acute decompensated heart failure with cardiogenic shock features (hypotension, tachycardia, poor perfusion), a state in which the negative inotropic effect of beta blockers can worsen hemodynamic instability. In this acute setting, the beta blocker dose should be reduced or temporarily withheld until the patient is hemodynamically stabilized with inotropes or other supportive measures, after which it can be cautiously reintroduced. This differs from chronic stable HFrEF, where beta blockers like carvedilol, bisoprolol, and metoprolol succinate are proven to reduce mortality by blunting sympathetic-mediated cardiac remodeling. Increasing or switching doses acutely would risk further hemodynamic deterioration.

• A. Increasing the dose during acute decompensation would worsen hypotension and perfusion.
• C. Switching to another beta blocker at a higher dose would still worsen the acute hemodynamic compromise.
• D. Continuing the same dose ignores the hemodynamic instability requiring dose adjustment.